• Fri, March 3, 2023

Mark Breidenbach Maintained (SYRS) at Buy with Decreased Target to $13 on, Mar 3rd, 2023

Mark Breidenbach of Oppenheimer, Maintained "Syros Pharmaceuticals, Inc." (SYRS) at Buy with Decreased Target from $15 to $13 on, Mar 3rd, 2023.

Mark has made no other calls on SYRS in the last 4 months.



There are 2 other peers that have a rating on SYRS. Out of the 2 peers that are also analyzing SYRS, 0 agree with Mark's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Mark


  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $20 on, Thursday, January 5th, 2023
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $16 on, Tuesday, November 15th, 2022

Like: 👍